Acasti Pharma, FDA Agree on GTX-104 Phase 3 Trial Protocol
By Robb M. Stewart
Acasti Pharma said Wednesday it has aligned with the U.S. Food and Drug Administration on the protocol for its late-stage trial of its lead clinical asset, GTX-104.
The Quebec-based biopharmaceutical company also said it has received guidance from the regulator on a potential new drug application package for a novel injectable nimodipine formulation administered under intravenous infusion.
Acasti said it has all the necessary information from the FDA to initiate its Phase 3 trial of GTX-104 to evaluate the drug candidate's safety and tolerability profile relative to oral nimodipine as a treatment for aneurysmal subarachnoid hemorrhage, a rare and life-threatening medical emergency.
Acasti said its expects to dose the first Phase 3 trial patient in the fourth quarter and its current cash runway to be sufficient in funding a potential new drug application submission for GTX-104 in the first half of 2025.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
July 05, 2023 09:37 ET (13:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters